RUNX1 and central nervous system cancer: Furthermore, RUNX1 was further over-expressed in grade IV glioma (GBM) patients in TCGA (P = 1.8E−18) and CGGA (P = 0.002) datasets (Fig. 4g), suggested the increased expressions of RUNX1 with the increased malignance of glioma.